SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Strategies to achieve fairer prices for generic and biosimilar medicines
15 references·1 citing·48 second hop
Strategies to achieve fairer prices for generic and biosimilar medicines (2020)Strategies to achieve fairer prices for g…Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal (2024)Two new Later Stone Age sites…The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review (2018)The Impact of Patent Expiry o…Pathways to ensure universal and affordable access to hepatitis C treatment (2018)Pathways to ensure universal …Medicines reimbursement policies in Europe (2018)Medicines reimbursement polic…Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016 (2018)Medicine procurement and the …Policy objective of generic medicines from the investment perspective: The case of clopidogrel (2017)Policy objective of generic m…Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries (2017)Do changes to supply chains a…Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending (2017)Comparing Generic Drug Market…What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs (2015)What do people really think o…Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review (2015)Perceptions of generic medica…Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014)Pharmaceutical policies: effe…The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use (2013)The experiences of implementi…The economics of biosimilars. (2013)The economics of biosimilars.Competition in off-patent drug markets: Issues, regulation and evidence (2008)Competition in off-patent dru…Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2006)Pharmaceutical policies: effe…Integrative Review of Managed Entry Agreements: Chances and Limitations (2020)Integrative Review of Managed…INTERRUPTED TIME SERIES DESIGNS IN HEALTH TECHNOLOGY ASSESSMENT: LESSONS FROM TWO SYSTEMATIC REVIEWS OF BEHAVIOR CHANGE STRATEGIES (2003)Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration (2008)Pharmaceutical policies: effects of cap and co-payment on rational drug use (2008)GRADE guidelines: 3. Rating the quality of evidence (2011)Cost-Containment Policies in Public Pharmaceutical Spending in the EU (2012)Policies to promote use of generic medicines in low and middle income countries: A review of published literature, 2000–2010 (2012)How can systematic reviews incorporate qualitative research? A critical perspective (2006)Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses (2007)Critically appraising qualitative research (2008)Medicine shortages in Fiji: A qualitative exploration of stakeholders’ views (2017)Perceptions of the quality of generic medicines: implications for trust in public services within the local health system in Tumkur, India (2018)Out-of-pocket payments in the context of a free maternal health care policy in Burkina Faso: a national cross-sectional survey (2019)European Healthcare Policies for Controlling Drug Expenditure (2003)The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending (2003)Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis (2008)Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? (2014)The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians (2015)The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries (2019)The Theory of Industrial Organization (1988)Theory of Industrial Organization. (1989)Impact of European Pharmaceutical Price Regulation on Generic Price Competition (2010)Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs (2013)Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development (2013)Econometric Analysis of Panel Data (2021)The Measurement of Observer Agreement for Categorical Data (1977)Cochrane Handbook for Systematic Reviews of Interventions (2008)Patients’ Perceptions Of Generic Medications (2009)Making the Medieval Relevant (2019)Medicines shortages in Pakistan: a qualitative study to explore current situation, reasons and possible solutions to overcome the barriers (2019)Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States (2014)Expenditure on retail pharmaceuticals per capita, 2016 (2018)What is the impact of intellectual property rules on access to medicines? A systematic review (2022)Decentralization of health systems in Ghana, Zambia, Uganda and the Philippines: a comparative analysis of decision space (2002)Getting Health Reform Right: A Guide to Improving Performance and Equity (2003)Getting Health Reform Right (2008)The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China (2020)Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis (2021)Pooled procurement of drugs in low and middle income countries (2021)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Essential medicines for universal health coverage (2016)United States Health Care Reform (2016)Challenges and opportunities for incentivising antibiotic research and development in Europe (2023)Orphan Drugs and Their Impact on Pharmaceutical Development (2018)Why Are Biosimilars Not Living up to Their Promise in the US? (2019)Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities (2022)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration (2009)ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions (2016)AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both (2017)
this work references cited by second hop

References

  • 2024Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal23,871 cited
  • 2017Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending287 cited
  • 2013The economics of biosimilars.225 cited
  • 2006Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies206 cited
  • 2015Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review198 cited
  • 2015What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs191 cited
  • 2013The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use159 cited
  • 2008Competition in off-patent drug markets: Issues, regulation and evidence140 cited
  • 2017Policy objective of generic medicines from the investment perspective: The case of clopidogrel136 cited
  • 2017Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries133 cited
  • 2018Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–201688 cited
  • 2018The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review86 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2014
Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies
84 cited
  • 2018Medicines reimbursement policies in Europe82 cited
  • 2018Pathways to ensure universal and affordable access to hepatitis C treatment76 cited
  • Cited by

    • 2020Integrative Review of Managed Entry Agreements: Chances and Limitations56 cited